The role of pemetrexed in the treatment of colorectal cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 54-56

  Hochster, Howard ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; DEXAMETHASONE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PEMETREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

EID: 0036980907     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70047-x     Document Type: Review

References (11)

1. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - an Eastern Cooperative Oncology Group/ Cancer and Leukemia Group B Study. J Clin Oncol 19:2413-2421, 2001
2. Meta-analysis Group: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992
3. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
5. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
6. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
7. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124a, 2001 (abstr 494)
8. Cripps C, Burnell M, Jolivet J, et al: Phase 11 study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 10:1175-1179, 1999
9. John W, Picus J, Blanke CD, et al: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study. Cancer 88:1807-1813, 2000
10. Paulson R, Hainsworth J, Geyer C, et al: A phase II trial of MTA (multiple targeted antifolate, LY231514) in patients with 5-FU and irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 18:297a, 1999 (abstr 1140)
11. Misset J-L, Gaemlin E, Campone M, et al: Pemetrexed/ oxaliplatin (LOHP) combination: Results of a phase I study in metastatic solid tumors. Proc Am Soc Clin Oncol 21:107a, 2002 (abstr 427)